FIG 2.

Sorafenib treatment does not affect intracellular Gn protein levels. (A) Schematic of the treatments used for the cells whose images appear in panels B to E. (B to E) Vero cells were infected with MP12 at an MOI of 10 and either treated with DMSO immediately following infection (B), treated with sorafenib immediately following infection (C), treated with sorafenib at 8 h postinfection (D), or treated with sorafenib at 10 h postinfection (E). (F) Cells were fixed, permeabilized, and stained for virus glycoprotein Gn both inside the cell and on the cell surface at 12 h postinfection. The percentage of cells that stained positive for Gn expression was determined by high-content quantitative image-based analysis (see Materials and Methods). The means and standard deviations from three biological replicates are plotted. (G) Cells were fixed, permeabilized, and stained for viral N protein both inside the cell and on the cell surface at 12 h postinfection. The percentage of cells that stained positive for N expression was determined by high-content quantitative image-based analysis (see Materials and Methods). The means and standard deviations from three biological replicates are plotted.